Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.92
PLX's Cash to Debt is ranked lower than
81% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. PLX: 0.92 )
Ranked among companies with meaningful Cash to Debt only.
PLX' s Cash to Debt Range Over the Past 10 Years
Min: 0.51  Med: 10000.00 Max: No Debt
Current: 0.92
Equity to Asset 0.03
PLX's Equity to Asset is ranked lower than
91% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. PLX: 0.03 )
Ranked among companies with meaningful Equity to Asset only.
PLX' s Equity to Asset Range Over the Past 10 Years
Min: -1.15  Med: -0.09 Max: 0.8
Current: 0.03
-1.15
0.8
F-Score: 3
Z-Score: -2.70
M-Score: -0.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 49427.78
PLX's Operating margin (%) is ranked higher than
100% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. PLX: 49427.78 )
Ranked among companies with meaningful Operating margin (%) only.
PLX' s Operating margin (%) Range Over the Past 10 Years
Min: -8239.43  Med: -235.53 Max: -34.91
Current: 49427.78
-8239.43
-34.91
Net-margin (%) -102612.96
PLX's Net-margin (%) is ranked lower than
98% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. PLX: -102612.96 )
Ranked among companies with meaningful Net-margin (%) only.
PLX' s Net-margin (%) Range Over the Past 10 Years
Min: -8103.09  Med: -241.38 Max: -33.32
Current: -102612.96
-8103.09
-33.32
ROA (%) 72.52
PLX's ROA (%) is ranked higher than
99% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. PLX: 72.52 )
Ranked among companies with meaningful ROA (%) only.
PLX' s ROA (%) Range Over the Past 10 Years
Min: -62.69  Med: -36.59 Max: -1.93
Current: 72.52
-62.69
-1.93
ROC (Joel Greenblatt) (%) -260.37
PLX's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. PLX: -260.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PLX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -711.06  Med: -202.32 Max: -9.14
Current: -260.37
-711.06
-9.14
Revenue Growth (3Y)(%) 18.10
PLX's Revenue Growth (3Y)(%) is ranked higher than
74% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. PLX: 18.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PLX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 325.1
Current: 18.1
0
325.1
EBITDA Growth (3Y)(%) -15.50
PLX's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. PLX: -15.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PLX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -38  Med: -14.50 Max: 83
Current: -15.5
-38
83
» PLX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

PLX Guru Trades in

PLX Guru Trades in

Q4 2015

PLX Guru Trades in Q4 2015

Jim Simons 20,933 sh (New)
» More
Q1 2016

PLX Guru Trades in Q1 2016

Jim Simons 54,900 sh (+162.27%)
» More
» Details

Insider Trades

Latest Guru Trades with PLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:KMPH, NAS:PBMD, NAS:TTHI, NAS:AGLE, OTCPK:HPPI, OTCPK:DYAI, NAS:XOMA, AMEX:CVM, NAS:NVET, AMEX:XXII, NAS:CHMA, NAS:DNAI, NAS:DRNA, NAS:CFRX, NAS:PIRS, NAS:TCON, NAS:OCRX, NAS:CALA, NAS:AVEO, NAS:SBPH » details
Traded in other countries:PBD.Germany, PLX.Israel,
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.

Protalix BioTherapeutics Inc was originally incorporated in the State of Florida in April 1992. It is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx. Using its ProCellEx system, it is developing a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins that target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Its initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The Company has developed ElelysoTM, its first drug product, ProCellEx will enable it to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. The Company is now also applying the properties of its ProCellEx system for the oral delivery of therapeutic proteins. The Company relies on a single approved supplier for certain materials relating to the current expression of its proprietary biotherapeutic proteins through ProCellEx. It faces competition from companies with approved treatments of Gaucher disease. Some such companies include iBio, Inc., Medicago Inc., and Greenovation Biotech GmbH. The Company has 94 pending patent applications and one joint pending patent application with a third party. The Company is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar authorities in other countries.

Ratios

vs
industry
vs
history
P/E(ttm) 1.08
PLX's P/E(ttm) is ranked higher than
98% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.09 vs. PLX: 1.08 )
Ranked among companies with meaningful P/E(ttm) only.
PLX' s P/E(ttm) Range Over the Past 10 Years
Min: 1.07  Med: 1.36 Max: 1.69
Current: 1.08
1.07
1.69
P/B 24.07
PLX's P/B is ranked lower than
95% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. PLX: 24.07 )
Ranked among companies with meaningful P/B only.
PLX' s P/B Range Over the Past 10 Years
Min: 7.25  Med: 61.62 Max: 129.09
Current: 24.07
7.25
129.09
Current Ratio 8.22
PLX's Current Ratio is ranked higher than
70% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. PLX: 8.22 )
Ranked among companies with meaningful Current Ratio only.
PLX' s Current Ratio Range Over the Past 10 Years
Min: 1.72  Med: 5.00 Max: 72.77
Current: 8.22
1.72
72.77
Quick Ratio 7.60
PLX's Quick Ratio is ranked higher than
68% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. PLX: 7.60 )
Ranked among companies with meaningful Quick Ratio only.
PLX' s Quick Ratio Range Over the Past 10 Years
Min: 1.45  Med: 5.00 Max: 72.77
Current: 7.6
1.45
72.77

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 21.67
PLX's Price/Tangible Book is ranked lower than
92% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. PLX: 21.67 )
Ranked among companies with meaningful Price/Tangible Book only.
PLX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.34  Med: 1.94 Max: 110.55
Current: 21.67
0.34
110.55
Earnings Yield (Greenblatt) (%) -37.65
PLX's Earnings Yield (Greenblatt) (%) is ranked lower than
80% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. PLX: -37.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PLX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -38.27  Med: 5037.85 Max: 12682.8
Current: -37.65
-38.27
12682.8

More Statistics

EPS (TTM) $ 0.59
Beta0.21
Short Percentage of Float0.95%
52-Week Range $0.61 - 1.78
Shares Outstanding (Mil)99.81
» More Articles for PLX

Headlines

Articles On GuruFocus.com
Avago Technologies' Memory, FBAR, and Connectivity Business Will Take It Higher Oct 23 2014 
Weekly CFO Sells Highlight: AXP, CRAY, PLX, KMB, ITW, CATM, CAR May 07 2012 
Protalix BioTherapeutics Inc Reports Operating Results (10-K) Feb 23 2011 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Nov 08 2010 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares Oct 08 2010 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares Sep 08 2010 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Aug 05 2010 
Protalix BioTherapeutics Inc (PLX) CEO and President David Aviezer sells 244,238 Shares Oct 21 2009 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 150,000 Shares Oct 19 2009 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Aug 03 2009 

More From Other Websites
Update: VMob Group Limited Name Change Jul 25 2016
Protalix BioTherapeutics Announces First Patient Dosed in the AIR DNase™ Phase II Clinical Trial... Jul 07 2016
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Jul 07 2016
Protalix BioTherapeutics Announces First Patient Dosed in the AIR DNase™ Phase II Clinical Trial... Jul 07 2016
Point Loma Resources Ltd. Will Open for Trading July 5, 2016 on TSXV Jul 04 2016
IIROC Trading Resumption - PLX Jul 04 2016
IIROC Trading Resumption - PLX Jul 04 2016
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Jun 07 2016
Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial of Fabry Disease to... Jun 06 2016
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Jun 06 2016
Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial of Fabry Disease to... Jun 06 2016
Protalix BioTherapeutics to Present at the Jefferies 2016 Global Healthcare Conference Jun 02 2016
Protalix BioTherapeutics to Present at the Jefferies 2016 Global Healthcare Conference Jun 02 2016
Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2016 By the Numbers : May 19, 2016 May 19 2016
Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
PROTALIX BIOTHERAPEUTICS, INC. Financials May 17 2016
Protalix reports 1Q loss May 09 2016
Protalix reports 1Q loss May 09 2016
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition May 09 2016
Protalix BioTherapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update May 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)